|
gptkbp:instanceOf
|
gptkb:norepinephrine_reuptake_inhibitor
gptkb:drug
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AX21
|
|
gptkbp:brand
|
gptkb:Cymbalta
Yentreve
|
|
gptkbp:CASNumber
|
gptkb:136434-34-9
|
|
gptkbp:chemicalFormula
|
C18H19NOS·HCl
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
uncontrolled narrow-angle glaucoma
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:drugClass
|
gptkb:analgesic
gptkb:antidepressant
gptkb:benzodiazepine
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
333.88 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
fatigue
drowsiness
dry mouth
increased sweating
|
|
gptkbp:synonym
|
gptkb:LY248686
gptkb:duloxetine
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
fibromyalgia
chronic musculoskeletal pain
diabetic peripheral neuropathic pain
|
|
gptkbp:bfsParent
|
gptkb:Cymbalta
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
duloxetine hydrochloride
|